Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Accumulated Expenses (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Accumulated Expenses for 8 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 127.44% to $1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a 127.44% increase, with the full-year FY2025 number at $1.4 million, changed N/A from a year prior.
  • Accumulated Expenses was $1.6 million for Q4 2025 at Outlook Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $5.3 million in Q2 2025 to a low of $683479.0 in Q4 2024.